Johns Hopkins Venous Thromboembolism Symposium
The Johns Hopkins Venous Thromboembolism (VTE) Collaborative, with support the Department of Medicine at the Johns Hopkins University School of Medicine, the Department of Surgery at Johns Hopkins, the Russell H. Morgan Department of Radiology and Radiological Science, the Department of Pharmacy and Johns Hopkins Nursing, in collaboration with the Armstrong Institute for Patient Safety and Quality, holds a VTE symposium every March that highlights some of the latest research on venous thromboembolism and features a keynote speaker who is an international authority in this field.
Save the Date!
18th Annual Johns Hopkins Medicine VTE Symposium
March 27, 2026
Keynote speaker: Scott Kaatz, D.O., M.Sc., F.A.C.P., S.F.H.M.
Scott Kaatz is Clinical Professor of Medicine at Michigan State University College of Human Medicine and Wayne State University School of Medicine and a hospitalist at Henry Ford Hospital in Detroit and Co-director of the anticoagulation clinics for which he founded. He attended medical school at Michigan State University and completed his residency in internal medicine at Henry Ford Hospital. Later in his career, he earned his master’s degree in Evidence-Based Health Care from Oxford University.
Dr. Kaatz is a Fellow of American College of Physicians and a Senior Fellow Society of Hospital Medicine. He is a past President of the Anticoagulation Forum, Thrombosis and Hemostasis Societies of North America and the Michigan Chapter of the Society of Hospital Medicine.
He also served on several national boards including the Medical Scientific Advisory Board of the National Blood Clot Alliance the Anticoagulation Forum, PERT Consortium and National Certification Board of Anticoagulation Providers.
He has participated in many research studies with an emphasis on anticoagulation, atrial fibrillation, peri-procedural anticoagulation and venous thromboembolism prevention, diagnosis, and treatment; and has published over 350, articles, book chapters and abstracts in this field.
This event is free to all.
This offering is partially supported by the Department of Medicine at the Johns Hopkins University School of Medicine, the Department of Surgery at Johns Hopkins, the Russell H. Morgan Department of Radiology and Radiological Science, the Department of Pharmacy and Johns Hopkins Nursing, in collaboration with the Armstrong Institute for Patient Safety and Quality.
Past VTE Symposia
-
Watch the recording | Download agenda (.pdf)
Keynote Speaker: Allison Burnett, Pharm.D., Ph.C., C.A.C.P.
Dr. Burnett received her pharmacy doctorate from the University of New Mexico College of Pharmacy in 2003, then completed a general pharmacy practice residency at Boston Medical Center in 2004. She now serves as lead pharmacist of the Inpatient Antithrombosis Stewardship program at the University of New Mexico Health Sciences Center and as an associate adjunct clinical professor at the UNM College of Pharmacy. She has published more than 50 peer-reviewed articles and book chapters on anticoagulation, thrombosis and bleeding management and has presented on these same topics at numerous national and international conferences. She sits on the National Certification Board for Anticoagulation Providers and has the distinct honor of serving as the current president of the Anticoagulation Forum, a national nonprofit organization with the mission of educating and empowering multidisciplinary clinicians toward optimized stewardship of anticoagulant therapies.
-
Watch the recording | Download the agenda
Perioperative Anticoagulant Management: Five Developments in 2024 That Will Affect Your Practice
Keynote Speech: James DouketisJames Douketis is a staff physician in general internal medicine and clinical thromboembolism at St. Joseph’s Healthcare Hamilton in Canada. A professor of medicine, he holds the David Braley-Nancy Gordon Chair in Thromboembolic Disease at McMaster University, also in Canada. He received his M.D. and performed a residency in internal medicine at the University of Toronto, followed by a thrombosis fellowship at McMaster University.
His research interests include perioperative anticoagulant management and related guideline development (2008, 2012, 2022 ACCP Guidelines), and venous thromboembolism prevention, treatment and prognosis for patients.
Douketis is a fellow of the Canadian Academy of Health Science, past president of Thrombosis Canada (2013–21), editor-in-chief of the Canadian Journal of General Internal Medicine, associate editor of the McMaster Textbook of Internal Medicine, deputy editor of the Annals of Internal Medicine’s “Journal Club” and associate editor of Thrombosis and Haemostasis. He has 430 peer-reviewed publications, with an h-index=100, i-index=281, and ~107K citations (July 2023).
James Douketis lives in Hamilton, Ontario, Canada, with his wife, clinical geneticist Margaret Nowaczyk. He has two sons, Jack and Luke. Douketis is a cellist with the Burlington Symphony Orchestra.
-
Update on the Management of Cancer-associated Thrombosis
Keynote: Marc Carrier, MD, MSc, FRCPC
Dr. Marc Carrier, M.D., MSc, FRCPC, is Head of the Division of Hematology at The Ottawa Hospital, a Professor in the Faculty of Medicine, Department of Medicine and Senior Scientist in the Clinical Epidemiology Program of The Ottawa Hospital Research Institute. He holds a Tier 1 Research Chair in Venous Thromboembolism and Cancer from the Faculty of Medicine at the University of Ottawa. His clinical research is focused in venous thromboembolic disease and cancer, including cancer screening, prevention and management.
The Psychological Impact of Thrombosis in Athletes and Exercisers
Patient Speaker: Julie A. Partridge, PhD, CMPC
Dr. Partridge is an Associate Professor of Kinesiology and Faculty Athletics Representative (FAR) at Southern Illinois University. Her primary focus is in the sub disciplinary area of sport and exercise psychology. She also serves as Director of the Social Psychology of Sport Laboratory.
-
Progress in Direct Oral Anticoagulant Reversal Therapy
Keynote: Jack E. Ansell, MD, MACPDr. Jack Ansell is former Chair of Medicine, Lenox Hill Hospital and Professor of Medicine at Hofstra-Northwell School of Medicine. He is a clinical investigator with a principal focus on the clinical problems of thrombosis, antithrombotic therapy, and the application of new modes of delivering and monitoring anticoagulants. Prior to his position in New York, Dr. Ansell was a Professor of Medicine and Vice Chairman of the Department of Medicine at Boston University School of Medicine.
Dr. Ansell has helped to identify and provide an understanding of the problems related to the management of warfarin therapy and was one of the first investigators to identify and show that patients can manage their own therapy through home monitoring. He has been a leader in the promotion of high quality anticoagulation management through the development of anticoagulation clinics and was founder and president for over 15 years of the Anticoagulation Forum, which has grown into a 13,000 member organization representing over 2,500 anticoagulation clinics and interfacing with over 1 million patients. He has more recently been involved with clinical trials of the direct oral anticoagulants and in the development of reversal agents for these anticoagulants.
Dr. Ansell has authored over 250 peer reviewed manuscripts and numerous textbook chapters and a number of texts. He was the lead author for over 10 years of the major consensus guidelines for antithrombotic therapy through the American College of Chest Physicians Consensus Conference on Antithrombotic Therapy, and is lead editor of a unique textbook entitled Managing Oral Anticoagulation: Clinical and Operational Guidelines. Dr. Ansell also held a leadership position in the National Blood Clot Alliance, a patient advocacy group, as past Chair of the Medical and Scientific Advisory Board. Dr. Ansell is a Master of the American College of Physicians and a Fellow of the American Heart Association. Dr. Ansell received his medical degree from the University of Virginia School of Medicine and completed his medical residency at Tufts-New England Medical Center in Boston, followed by a fellowship in Hematology at Boston University and the Boston’s Veterans Administration Hospital.
-
Watch the recording | Download the agenda
Thrombotic Complications of COVID-19: Etiology, Prognosis and Prevention
Keynote: Suzanne Cannegieter, MD, PhD, MScSuzanne Cannegieter is a professor of Clinical Epidemiology at the Leiden University Medical Center in the Netherlands. She focuses her research on venous thrombo-embolism, with a particular interest in its etiology, as well as in establishing optimal prevention and therapy. She is involved in several national multicenter studies as PI, WP leader or methodological advisor. For her studies she combines the latest epidemiological and statistical techniques with pathophysiological and clinical knowledge.
Suzanne Cannegieter is a member of the Scientific Advisory Board of the Dutch Thrombosis Foundation. She is Associate Editor for ‘Research and Practice in Thrombosis and Haemostasis’ and member of the Editorial Board for the Journal of Thrombosis and Haemostasis and PLoS Medicine. She was board member of the Netherlands Society for Thrombosis and Haemostasis (NVTH) and was a member of the Local Organizing Committee (Education) for the 24th Congress of ISTH, held in Amsterdam 2013. She is also past member of the Education Committee of the Council of the International Society on Thrombosis and Haemostasis (ISTH) and past co-chair of the ISTH Scientific Subcommittee on Predictive and Diagnostic Variables.
-
Prediction and Treatment of Cancer-Associated Thrombosis
Keynote: Alok Khorana, MD, FACP, FASCOAlok Khorana, M.D., is a professor of medicine at the Cleveland Clinic Lerner College of Medicine, Case Western Reserve University; the Sondra and Stephen Hardis Chair in Oncology Research and vice chair for clinical services at the Taussig Cancer Institute (part of the Cleveland Clinic Cancer Center); and director of the gastrointestinal malignancies program at the Cleveland Clinic. His clinical and translational research program focuses on predictive factors and drug development for cancer-associated thrombosis and gastrointestinal cancers, and has been funded by grants from the National Cancer Institute, the National Heart, Lung, and Blood Institute, the Hardis family, the Porter Family Fund, VeloSano, the Cleveland Clinic Center for Excellence, the Scott Hamilton CARES Initiative, Stand Up to Cancer (colorectal cancer Dream Team) and the V Foundation for Cancer Research.
Dr. Khorana received his medical degree from Maharaja Sayajirao University’s medical college in Baroda (now Vadodara, Gujarat), India. His postdoctoral training included a residency in internal medicine at the University at Buffalo in New York and a fellowship in hematology and oncology at the University of Rochester, also in New York. He is a fellow of the American College of Physicians, and in 2018, he was elected a fellow of the American Society of Clinical Oncology.
Dr. Khorana is past chair of the American Society of Clinical Oncology (ASCO) Clinical Practice Guidelines Panel (CPGP), chair of the ASCO CPGP Pancreas Cancer Working Group, and co-chair of the ASCO CPGP Multisite Advisory Group and the ASCO Guidelines Panel on Resectable Pancreas Cancer. He has served on the ASCO Scientific Program Committee, the U.S. Pharmacopoeia Oncology Expert Committee and guidelines/guidance panels for organizations including ASCO, the American Society of Hematology, the American Society for Radiation Oncology and the International Society on Thrombosis and Haemostasis (ISTH). He was also chair of the ISTH Scientific Subcommittee on Hemostasis and Malignancy. In 2019, Dr. Khorana received the Cleveland Clinic’s Maria and Sam Miller Professional Excellence Award for scientific achievement in clinical research.
Dr. Khorana’s work has been published in a variety of journals including The New England Journal of Medicine, Journal of the American Medical Association (JAMA), Journal of Clinical Oncology, Blood, Journal of the National Cancer Institute, Clinical Cancer Research, PLOS One and JAMA Internal Medicine.He has co-authored chapters in multiple textbooks including editions of Cecil Essentials of Medicine and Cancer — Principles & Practice of Oncology, and he isco-editor of the book Cancer-Associated Thrombosis — New Findings in Translational Science, Prevention and Treatment. Dr. Khorana’s fiction and creative nonfiction works have been published in the Bellevue Literary Review, Annals of Internal Medicine and Health Affairs, and selected for The Best American Medical Writing.
-
Extending Thromboprophylaxis in Medically Ill Patients
Keynote: Alex C. Spyropoulos, MD, FACP, FCCP, FRCPCAlex C. Spyropoulos, MD received his medical degree from the University of Pennsylvania School of Medicine in Philadelphia, PA. He completed his internship and residency in internal medicine at the University of New Mexico Health Sciences Center in Albuquerque, NM. He is board certified in Internal Medicine.
Dr. Spyropoulos was Founder and former Medical Director of the Clinical Thrombosis Center in Albuquerque, New Mexico. He is a Professor of Medicine at Hofstra, Northwell School of Medicine and System Director of Anticoagulation and Clinical Thrombosis Services for the multi hospital Northwell Health System in NY. He is also a Professor of the Center for Health Innovations and Outcomes Research as part of the Feinstein Institute for Medical Research. He is co-chair of the Council on Leadership of Thrombosis at Northwell Health System. He is a Fellow of the American College of Physicians, American College of Chest Physicians, International Academy of Clinical and Applied Thrombosis/Haemostasis, and the Royal College of Physicians, Canada.
Dr. Spyropoulos has helped to develop protocols using LMWH in outpatient-based treatment of venous thromboembolic disease, patient self-testing of warfarin, perioperative “bridging” for patients on chronic anticoagulation, medical inpatient thromboprophylaxis, protocols with regards to the use of anticoagulants for HIT, and clinical use of the direct oral anticoagulants, including their use in special patient populations and periprocedural situations. Dr. Spyropoulos is active in assessing outcome and pharmacoeconomic analyses of these protocols and has lectured extensively both nationally and internationally on these issues.
He has been involved as Principal Investigator, Scientific Committee member, Steering and Executive Committee member, or member of Data Safety Monitoring Board in multiple international, multicenter randomized trials in thrombosis and anticoagulant therapy, including the NHLBI BRIDGE and NHLBI Kids DOTT studies and the CIHR PAUSE trial. He is the co-Chair of the Executive Committee for MARINER, a global Phase 3 multicenter study of thromboprophylaxis in medical patients with rivaroxaban, He is a founding member of ATLAS, a US-based ARO-CRO in thrombosis-related research. He is a panel member of a US national experts consensus group for clinical excellence in thrombosis management, a member of the Anticoagulation Forum and the Thrombosis/Haemostasis Society of North America, co-Chair of the Scientific Standardization Committees of Perioperative Thrombosis and Haemostasis as part of International Society of Thrombosis and Haemostasis, and co-author for the 8th, 9th and currently 10th 2018 ACCP Guidelines on Perioperative Antithrombotic Therapy, the 2008 International Consensus Statement Guidelines in Venous Thromboembolism, and senior author for the 2013 International Consensus Statement on venous thromboembolic disease. He is also reviewer for the 2014 ESC Guidelines on Pulmonary Embolism. He is Section Editor for Thrombosis and Haemostasis, and is on the editorial staff for Hospital Medicine. He is a reviewer for many journals.
Dr. Spyropoulos’ research studies, articles, letters, and editorials have been published in over 170 peer-reviewed journals including The New England Journal of Medicine, Blood, Circulation, Annals of Internal Medicine, American Journal of Hematology, American Journal of Medicine, Chest, Thrombosis Haemostasis, American Journal of Cardiology, Journal of Thrombosis and Haemostasis , Journal of the American College of Cardiology, Clinical Applied Thrombosis and Haemostasis, and Thrombosis Research.
-
Watch the recording | Download the agenda
Bringing Epidemiology to Life in Venous Thromboembolism
Keynote: Mary Cushman, M.D., M.Sc.Dr. Cushman is a hematologist at the University of Vermont Medical Center and a professor of medicine and pathology at the Larner College of Medicine at University of Vermont. Serving as the medical director of the Thrombosis and Hemostasis Program, she is an expert in the care of patients with venous thrombosis and its complications, with an emphasis on tailoring treatments to an individual's level of risk, and on evaluations for inherited and acquired hypercoagulable syndromes when appropriate.
View her academic profile and her clinical bio.
The symposium will begin with Dr. Cushman's Medical Grand Rounds, to be followed by a series of short talks showcasing various VTE-related research studies across Johns Hopkins Medicine, as well as a panel of patients sharing their experiences with blood clots.
-
Watch the recording | Download the agenda
Keynote Speaker: Suresh Vedantham, M.D.
A Professor of Radiology and Surgery and the Washington University School of Medicine in St. Louis, Dr. Vedantham is an experienced interventional radiologist who specializes in the delivery and clinical investigation of image-guided therapies for VTE. He has a robust clinical practice in which he sees patients with advanced VTE manifestations who are referred to him locally, nationally and internationally for treatment that often includes innovative, image-guided, endovascular procedures such as catheter-directed thrombolysis (CDT). Dr. Vedantham has made important contributions to refining CDT to enhance its safety, and to educating physicians on its appropriate use.
A leading clinical scientist in the field of thrombosis, he serves as National Principal Investigator of the recently completed 66-site, NHLBI-sponsored ATTRACT Trial that has rigorously evaluated if CDT should be routinely used in patients with acute deep vein thrombosis. Dr. Vedantham also serves as Director of the Administrative Core of Washington University’s National Heart, Lung, and Blood Institute (NHLBI)-sponsored Center for Translational Therapies in Thrombosis, and as Co-Chair of the NHLBI’s Work Group on "Designing and Implementing Trials for Uncommon Diseases and Therapeutics."
Dr. Vedantham's presentation will be followed by a series of short talks showcasing VTE-related research studies across Johns Hopkins Medicine. The event will conclude with a patient panel discussion.
-
Keynote speaker: Richard White, M.D.
Learn about the latest efforts to prevent venous thromboembolism across Johns Hopkins Medicine at this year's symposium. The event will feature:
- Medical Grand Rounds by Richard White, M.D., Chief of General Medicine and Director of the Anticoagulation Service at the University of California
-
Short presentations showcasing VTE-related research studies
-
A panel of patients discussing their personal experiences with blood clots
-
Keynote speaker: Mark Crowther, M.D., M.Sc., F.R.C.P.C.
Mark Crowther, Leo Pharma Chair in Thomboembolism Research at McMaster University in Canada. Crowther’s research endeavors examine the optimal methods to prevent and treat both arterial and venous thrombosis.
His talk will be followed by a series of short talks showcasing VTE-related research studies across Johns Hopkins Medicine. It will conclude with a panel discussion.
-